Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

frovatriptan

&times

Overview

What is Frovatriptan?

Frovatriptan succinate tablets contain frovatriptan succinate, a selective 5-hydroxy-tryptamine (5-HT) receptor subtype agonist (triptan), as the active ingredient. Frovatriptan succinate is chemically designated as (3)-2,3,4,9-Tetrahydro-3-(methylamino)-1-carbazole-6-carboxamide succinate monohydrate and it has the following structure:

The molecular formula is CHNO•CHO•HO, representing a molecular weight of 379.41. Frovatriptan succinate is a white to off-white powder that is soluble in water.

Each frovatriptan succinate tablet for oral administration contains 3.91 mg frovatriptan succinate, equivalent to 2.5 mg of frovatriptan base. Each tablet also contains the inactive ingredients anhydrous lactose, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate and titanium dioxide.



What does Frovatriptan look like?



What are the available doses of Frovatriptan?

Tablets: 2.5 mg ()

What should I talk to my health care provider before I take Frovatriptan?

How should I use Frovatriptan?

Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use:

Dosing Information:

If the migraine recurs after initial relief, a second tablet may be taken, providing there is an interval of at least 2 hours between doses. The total daily dose of frovatriptan should not exceed three tablets (3 x 2.5 mg per 24 hour period).

There is no evidence that a second dose of frovatriptan succinate tablets is effective in patients who do not respond to a first dose of the drug for the same headache.

The safety of treating an average of more than four migraine attacks in a 30-day period has not been established.


What interacts with Frovatriptan?

Sorry No Records found


What are the warnings of Frovatriptan?

Sorry No Records found


What are the precautions of Frovatriptan?

Sorry No Records found


What are the side effects of Frovatriptan?

Sorry No records found


What should I look out for while using Frovatriptan?

Frovatriptan succinate tablets are contraindicated in patients with:


What might happen if I take too much Frovatriptan?

The elimination half-life of frovatriptan is 26 hours . Therefore, monitoring of patients after overdose with frovatriptan should continue for at least 48 hours or while symptoms or signs persist. There is no specific antidote to frovatriptan. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of frovatriptan.


How should I store and handle Frovatriptan?

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [seeUSP Controlled Room Temperature]. Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.The 2.5 mg tablets are white to off-white film-coated, round, unscored tablets debossed with on one side of the tablet and over on the other side. They are available as follows:NDC 0378-3140-59bottles of 9 tabletsNDC 0378-3140-93bottles of 30 tabletsNDC 0378-3140-85carton of 9 unit-dose tablets (1 x 9)Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Frovatriptan binds with high affinity to 5-HT receptors. The therapeutic activity of frovatriptan is thought to be due to the agonist effects at the 5-HT receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Non-Clinical Toxicology
Frovatriptan succinate tablets are contraindicated in patients with:

Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.

        Antacids may interfere with the absorption of hyoscyamine sulfate.

Frovatriptan is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of frovatriptan. Some of these reactions occurred in patients without known CAD. Frovatriptan may cause coronary artery vasospasm (Prinzmetal’s angina), even in patients without a history of CAD.

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving frovatriptan. Do not administer frovatriptan if there is evidence of CAD or coronary artery vasospasm . For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administrating the first frovatriptan dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following frovatriptan administration. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of frovatriptan.

The following adverse reactions are described elsewhere in other sections of the labeling:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).